Labatec Pharma Launches Eroxon® in the UAE

Labatec Pharma, a leading Swiss-based pharmaceutical company, has announced the UAE launch of Eroxon®, an innovative gel-based topical treatment for erectile dysfunction (ED). The UAE becomes the first market in the Middle East where the treatment is available following its recent regulatory approval. Distribution and retailing of the product inside the UAE will commence in October with Eroxon® available over the counter at local pharmacies.

Eroxon® is a U.S. FDA-approved over the counter erectile dysfunction topical treatment. Eroxon is also approved as a CE device in Europe and the United Kingdom. Studies have demonstrated that it presents an effective, clinically proven treatment for erectile dysfunction with a rapid speed of onset and a favourable benefit versus risk profile, which is ideally suited for an over-the-counter classification. It is therefore of particular appeal to mild to moderate ED patients.

Earlier this year, Labatec Pharma was selected as the partner to market Eroxon® in the Middle East, having acquired the product rights from Futura Medical – the global producer of MED3000 which is commercialized under the brand name Eroxon®. Labatec is collaborating with Alphamed, a healthcare brand under Al Khayyat Investments (AKI), as a distribution partner for Eroxon® in the UAE.

Faisal Darwazeh, CEO of Labatec Pharma, notes: “Labatec is proud to provide access to Eroxon® in the UAE. The inclusion of this innovative product in our portfolio illustrates Labatec’s strong commitment to improving men’s health in the region and around the world.”

James Barder, CEO of Futura Medical, says: “Globally, Eroxon® is a proven game changer in the treatment of erectile dysfunction. The launch of Eroxon® in the UAE represents an important milestone for men in the Middle East, and Futura is pleased to support its partner Labatec Pharma in launching Eroxon® in the local market.”

Professor David Ralph, Consultant Urologist at St Peter’s Andrology Centre & Institute of Urology, UCLH, London, adds: “The efficacy of Eroxon® is remarkable and approaches the efficacy of current first line therapy, but with significantly lower adverse events. As such, the product is of great interest to the medical community.”

Dr. Yasser Farahat, Chairman of the Arab School of Urology and IUCC Scientific Chair, comments: “The advancements seen in medications today can significantly contribute to improving the lives and relationships of individuals affected by erectile dysfunction. Raising awareness of and encouraging important conversations about ED are crucial in order to provide effective solutions.”

Dr. AbdulQadir Al Zarooni, President of the Emirates Urology Society, states: “Through great advancements in the field of urology, we are revolutionizing the treatment of erectile dysfunction in the UAE. Our mission is to restore not just physical function, but also the confidence and quality of life for our patients.”

Labatec made the announcement for commercial retailing of Eroxon® in the UAE during the 12th Emirates International Urological Conference recently held in Dubai.